Europe & Canada Business Unit (EUCAN) operates across 30 countries with its hub in Zurich, Switzerland. Our site is home to the EUCAN commercial organization, including the Vaccines Business Unit & key global functions including Medical Affairs, Market Access, Global Commercial, Manufacturing and Supply.
Takeda in Europe and Canada (EUCAN) is transforming into a Specialty Care company, delivering leading innovations in oncology and gastroenterology to provide better health and a brighter future for patients. By taking a people-focused approach, we aim to build trust with society and reinforce our reputation as a partner, translating those relationships into business growth.
Within EUCAN we are proud of the better outcomes delivered to patients by our key brands such as Entyvio (the first selective treatment for IBD) and Ninlaro (the first and only once-weekly oral proteasome inhibitor for relapsed refractory multiple myeloma). Always putting patients first, we are collaborating in the area of digital technology - harnessing the power of social media to improve patient outcomes and understanding the voice of patients.
Thurgauerstrasse 130, 8152 Glattpark-Opfikon (Zurich), Switzerland
+41 44 555 10 00
Internal Disclaimer Body